CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its ...

The Food and Drug Administration recently approved the IsoPSA blood test, which was developed by Cleveland Diagnostics, a ...

IsoPSA Test Evaluates Prostate Cancer-Specific Structural Variants of the PSA Protein to Aid in the Diagnosis of High-Grade Prostate Cancer Cleveland Diagnostics, Inc., a pioneering, commercial-stage ...

Cleveland Diagnostics said Monday it received Food and Drug Administration approval for a test that analyzes the structure of protein biomarkers in the blood for prostate cancer signals, to aid in ...

IsoPSA clinically validated in a study of over 1000 patients and demonstrates significant clinical utility in a study of 900 patients in a real-world setting CLEVELAND--(BUSINESS WIRE)--Cleveland ...

CLEVELAND - For men age 50 and over, the PSA, or prostate-specific antigen blood test, has been the recommended screening test for prostate cancer for years. It's also a test that some experts have ...

About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, but the screening process for this relatively common cancer isn’t always straightforward. Diagnosis can be a drawn-out and ...

Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that it has closed a Series D round ...

Update from the PSMA-dRT trial: A randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer. Test results of patients ...

Cleveland Diagnostics, maker of a prostate cancer screening test, has raised more than $75 million in growth capital funds to expand its approach to additional tumors. The financing was led by Novo ...

Cleveland Diagnostics Inc., a clinical-stage company that is developing diagnostic tests for the early detection of cancers, said it has closed a Series D financing round of $17.4 million. The round ...

IsoPSA Test Evaluates Prostate Cancer-Specific Structural Variants of the PSA Protein to Aid in the Diagnosis of High-Grade Prostate Cancer CLEVELAND, December 01, 2025--(BUSINESS WIRE)--Cleveland ...